Ezogabine (retigabine)

Nat Rev Drug Discov. 2011 Sep 30;10(10):729-30. doi: 10.1038/nrd3561.

Abstract

Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the U.S. Food and Drug Administration (F.D.A.) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

MeSH terms

  • Animals
  • Anticonvulsants / chemistry*
  • Anticonvulsants / pharmacokinetics
  • Anticonvulsants / therapeutic use*
  • Carbamates / chemistry*
  • Carbamates / pharmacokinetics
  • Carbamates / therapeutic use*
  • Epilepsies, Partial / drug therapy*
  • Epilepsies, Partial / metabolism
  • Humans
  • Phenylenediamines / chemistry*
  • Phenylenediamines / pharmacokinetics
  • Phenylenediamines / therapeutic use*
  • Randomized Controlled Trials as Topic / methods

Substances

  • Anticonvulsants
  • Carbamates
  • Phenylenediamines
  • ezogabine